Advertisement
INO vs LPCN
Which Stock Would AI Choose? Inovio Pharmaceuticals (INO) vs. Lipocine (LPCN) Stock Comparison
Key Takeaways
- INO (Inovio Pharmaceuticals) is a clinical-stage biotech built around DNA medicines, with its near-term outlook tied to an FDA decision on its lead candidate INO-3107 for recurrent respiratory papillomatosis (RRP), a rare airway disease.
- LPCN (Lipocine) is a specialty pharmaceutical company focused on oral drug delivery, anchored by the approved testosterone therapy TLANDO and an early-stage pipeline led by a postpartum depression candidate.
- Both names have suffered steep drawdowns over the past year, but they differ sharply in market cap, liquidity, cash runway, and the maturity of their respective lead programs.
- INO carries a larger near-term binary catalyst in its October 2026 PDUFA (Prescription Drug User Fee Act) review date, while LPCN's catalysts are spread across regulatory and clinical milestones.
- Neither company is profitable, and both face cash-burn and dilution risks that weigh on sentiment even as analyst price targets remain above current levels.
- For more detail on these names, explore the INO Major News and INO Today's Price Move pages, as well as the LPCN Major News and LPCN Today's Price Move pages.
- To see how automated systems are positioning across the market, review the curated Trending AI Robots list.
Introduction
Small-cap biotechnology and specialty pharmaceutical stocks attract a specific kind of investor: those comfortable with elevated volatility, binary regulatory events, and extended timelines to profitability. INO and LPCN both fit this profile, yet they operate in different corners of healthcare. Inovio is advancing a DNA-based immunotherapy platform, while Lipocine is built around proprietary oral delivery technology. Comparing the two offers a useful lens on how catalysts, balance-sheet strength, and market positioning can drive very different risk-reward profiles — even among stocks trading in similar price ranges. This stock comparison is most relevant to traders and investors weighing relative performance and momentum in the speculative healthcare segment.
INO Overview and Recent Performance
Inovio Pharmaceuticals (INO) develops "DNA medicines" designed to prompt the body to produce its own disease-fighting proteins, with a focus on HPV-related diseases, cancer, and infectious conditions. Its lead program, INO-3107, targets recurrent respiratory papillomatosis (RRP), a rare disorder causing recurring airway tumors. The U.S. Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) for review, setting a PDUFA goal date in late October 2026.
Recent market activity has been shaped by that regulatory timeline. The FDA assigned a standard, rather than accelerated, review classification and flagged questions about whether INO-3107 qualifies for the accelerated approval pathway — an uncertainty that has weighed on sentiment. On the financial side, Inovio has narrowed its losses through disciplined cost management, reporting a substantially smaller net loss in recent quarters, and raised additional capital to extend its cash runway into early 2027. Despite a constructive backdrop in late-stage review, the stock remains well below its 52-week high, reflecting both dilution and unresolved regulatory risk.
LPCN Overview and Recent Performance
Lipocine (LPCN) is a clinical-stage biopharmaceutical company focused on oral drug delivery technologies, with an emphasis on central nervous system (CNS) and endocrine disorders. Its commercial anchor is TLANDO, an oral testosterone replacement therapy, alongside an earlier-stage pipeline that includes LPCN 1154 (BRLIZIO), an oral neuro-steroid in development for postpartum depression.
In recent weeks, Lipocine delivered a notable catalyst when its licensing partner secured Health Canada approval for TLANDO, expanding the product's reach beyond its prior U.S. clearance. The company also initiated BLOOM, a Phase 3 pivotal trial for LPCN 1154, with first-patient dosing expected in the near term. Despite these advances, LPCN has underperformed substantially, with its share price down sharply on a year-to-date basis and trading near the lower end of its 52-week range. Thin trading volume, a modest market capitalization, and ongoing cash needs have contributed to a cautious tone among market participants.
Trending AI Robots
For traders looking to move beyond manual analysis, Tickeron offers a large library of AI Trading Bots that collectively monitor thousands of tickers across diverse strategies and timeframes. Because conditions shift constantly, only a fraction of these bots are featured in the curated Trending AI Robots section, which highlights the bots best suited to the current market environment. Each bot operates with its own trading style, holding period, risk profile, performance statistics, and universe of tickers, so no two are alike. This selection process is designed to surface the most relevant automated strategies rather than simply the most numerous. If you want to see which approaches are currently gaining traction, explore the Trending AI Robots page.
Head-to-Head Comparison
The clearest contrast between these two companies lies in the maturity and concentration of their pipelines. Inovio's investment case is heavily concentrated on a single late-stage candidate awaiting an imminent FDA decision, making its near-term performance highly sensitive to a binary regulatory outcome. Lipocine, by contrast, spreads its risk across an already-approved product (TLANDO) and several earlier-stage candidates, though its pipeline programs are generally less advanced and its revenue base remains minimal.
On the balance-sheet front, Inovio reports a larger cash position and has articulated a runway extending into early 2027, though recent capital raises have diluted shareholders. Lipocine's smaller market capitalization and lighter cash resources expose it to a different kind of pressure, including the possibility of further financing. Sector exposure also differs: Inovio sits in oncology and rare disease immunotherapy, while Lipocine operates across men's health and CNS conditions. Market sentiment for both has been cautious, with analyst targets well above current prices but actual trading momentum weak and volatility elevated.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst proximity, and relative stability, Tickeron's AI would likely lean toward INO over LPCN in the current environment. Inovio offers a defined, near-term catalyst in its PDUFA decision, a comparatively larger cash cushion, and a trend profile that has stabilized after deep losses. Lipocine's recent regulatory and clinical milestones are constructive but have yet to translate into sustained price momentum, and its smaller size introduces additional liquidity and financing risk. This assessment reflects probabilistic positioning rather than certainty — both names remain high-risk, catalyst-driven equities in a speculative segment of the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INO is a Hold and LPCN is a Hold.
INO in downward trend: price expected to drop as it breaks its higher Bollinger Band on November 02, 2026
INO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 33 similar instances where the stock broke above the upper band. In 29 of the 33 cases the stock fell afterwards. This puts the odds of success at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for INO moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 17 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 47 cases where INO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for INO entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on INO as a result. In 56 of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for INO just turned positive on November 02, 2026. Looking at past instances where INO's MACD turned positive, the stock continued to rise in 30 of 40 cases over the following month. The odds of a continued upward trend are 75%.
INO moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for INO crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in 185 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. INO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (28.741) is normal, around the industry mean (3.498). P/E Ratio (-1.180) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
LPCN in +12.42% Uptrend, growing for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where LPCN advanced for three days, in 209 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LPCN's RSI Oscillator exited the oversold zone, 29 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on LPCN as a result. In 66 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for LPCN just turned positive on November 02, 2026. Looking at past instances where LPCN's MACD turned positive, the stock continued to rise in 33 of 41 cases over the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
LPCN moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LPCN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
LPCN broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LPCN entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.595) is normal, around the industry mean (3.498). P/E Ratio (-0.849) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.302) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. LPCN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LPCN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
INO | LPCN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 92 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 42 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 36 | 75 | |
P/E GROWTH RATING 1..100 | 60 | 16 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LPCN's Valuation (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for INO (90) in the Medical Specialties industry. This means that LPCN’s stock grew somewhat faster than INO’s over the last 12 months.
LPCN's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as INO (100) in the Medical Specialties industry. This means that LPCN’s stock grew similarly to INO’s over the last 12 months.
LPCN's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as INO (100) in the Medical Specialties industry. This means that LPCN’s stock grew similarly to INO’s over the last 12 months.
INO's Price Growth Rating (36) in the Medical Specialties industry is somewhat better than the same rating for LPCN (75) in the Pharmaceuticals Other industry. This means that INO’s stock grew somewhat faster than LPCN’s over the last 12 months.
LPCN's P/E Growth Rating (16) in the Pharmaceuticals Other industry is somewhat better than the same rating for INO (60) in the Medical Specialties industry. This means that LPCN’s stock grew somewhat faster than INO’s over the last 12 months.
| INO | LPCN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 85% | 2 days ago 74% |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 84% |
| Momentum ODDS (%) | 2 days ago 79% | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 75% | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 76% | 2 days ago 86% |
| Advances ODDS (%) | 16 days ago 79% | 4 days ago 82% |
| Declines ODDS (%) | 7 days ago 88% | 21 days ago 86% |
| BollingerBands ODDS (%) | 2 days ago 88% | 2 days ago 83% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 81% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INO’s FA Score shows that 0 FA rating(s) are green while LPCN’s FA Score has 1 green FA rating(s).
- INO’s FA Score: 0 green, 5 red.
- LPCN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INO’s TA Score shows that 5 TA indicator(s) are bullish while LPCN’s TA Score has 4 bullish TA indicator(s).
- INO’s TA Score: 5 bullish, 5 bearish.
- LPCN’s TA Score: 4 bullish, 5 bearish.
Price Growth
INO (@Biotechnology) experienced а -8.95% price change this week, while LPCN (@Biotechnology) price change was +10.42% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
INO is expected to report earnings on Mar 02, 2027.
LPCN is expected to report earnings on Mar 11, 2027.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
INO and
Correlation & Price change
A.I.dvisor indicates that over the last year, INO has been loosely correlated with AXON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To INO | 1D Price Change % | ||
|---|---|---|---|---|
| INO | 100% | +1.72% | ||
| AXON - INO | 53% Loosely correlated | +4.26% | ||
| ARRY - INO | 52% Loosely correlated | +9.94% | ||
| LPCN - INO | 41% Loosely correlated | N/A | ||
| AMRN - INO | 39% Loosely correlated | -0.34% | ||
| PCSA - INO | 38% Loosely correlated | N/A | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DRMP | 15.52 | 1.26 | +8.80% |
| Tuttle Capital Memory Stack Income Blast ETF (DRMP) | |||
| EVIM | 52.30 | 0.06 | +0.11% |
| Eaton Vance Intermediate Municipal Income ETF (EVIM) | |||
| APRZ | 39.72 | N/A | N/A |
| TrueShares Structured Outcome (April) ETF (APRZ) | |||
| EPP | 55.97 | -0.02 | -0.04% |
| iShares MSCI Pacific ex-Japan ETF (EPP) | |||
| NMI | 9.59 | -0.02 | -0.19% |
| Nuveen Municipal Income | |||